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With its genome almost fully sequenced, the zebrafish has gone from bit player to rising star among 
model organisms. Its lower maintenance costs and the ease of tissue imaging in live zebrafish are 
among the benefits that have cast this organism as an emerging player in disease research and 
drug screening.The zebrafish is a small, active fish native 
to India. The hardiness of this striped fish 
makes it popular in home aquaria; aficio-
nados seeking a genetically modified pet 
can even buy transgenic GloFish. But the 
zebrafish, Danio rerio, is also the bright 
star among model organisms for biolo-
gists. Within the next year, the genome 
sequence of the zebrafish is expected 
to leap to a level of completeness for a 
vertebrate surpassed only by the human 
and the mouse genomes (http://www.
ensembl.org/Danio_rerio). This will hoist 
it toward the A-list of model organ-
isms. Already, the fish shows potential 
in studies of the basic biology of human 
diseases, including cancer, and in high-
throughput screens for drug discovery.
The zebrafish emerged as a potential 
model three decades ago and was put to 
work in the study of early development. 
Advances in cloning, mutagenesis, 
and transgenesis in zebrafish allowed 
invertebrate-style experiments on a 
vertebrate. Large genetic screens for 
randomly generated mutants began in 
Europe and the US in the early 1990s, on 
a scale usually associated with cultured 
cells or invertebrates. Basic numbers tell 
the story: one hundred fish fit in a 20 l 
tank and each female produces over two 
hundred embryos a week. Most organs 
are recognizable 24 hr after fertilization. 
Within 5 days of development, larvae are 
mobile and foraging.
Funders are keen on zebrafish as a 
model but could become keener when the 
complete genome sequence becomes 
available. “Within the NIH, there has 
been a steady trans-institute support 
for expanding the utility of zebrafish as a 
model organism,” says Shawn Burgess 
of the NIH’s Developmental Genomics 
Section in Bethesda, Maryland. “I think 
outside the NIH, because fish physiology 
is somewhat distant from its mammalian 
counterparts, there is still a lot of skepti-cism about whether zebrafish will have 
as central a role in human biomedical 
research as say mouse research does. 
Some skepticism is justified, but perhaps 
not enough emphasis is placed on how 
much cheaper research in zebrafish can 
be compared to mice, and how much 
can be learned from the differences as 
well as the similarities,” says Burgess.
“The zebrafish is underutilized in 
modeling in almost all areas of human 
disease,” according to Tim Chico of the 
UK’s MRC Centre for Developmental and 
Biomedical Genetics, who blames our 
mammal supremacist mindset. But fun-
damental cellular processes like devel-
opment of the vascular system, which he 
studies, are conserved across vertebrate 
species, and zebrafish bring a good haul 
of benefits to researchers. Chico points 
out that a fish costs 7 pence per week 
to maintain, whereas a mouse costs £4. 
Also, the zebrafish genome sequenc-
ing project begun in 2001 by the UK’s 
Wellcome Trust Sanger Institute has put 
reverse genetics on the menu. Key tech-
niques in use include TILLING (targeting 
local lesions in genomes), gene overex-
pression, knockdown models, and use 
of the yeast Gal4-UAS marker system.
Derek Stemple of the Sanger Institute 
says the eighth and final version of the 
zebrafish genome sequence at 6.5–7× 
coverage will be available next year. “It is 
85 to 90% complete. The trouble is that 
there is so much repetitive DNA, just like 
in humans, and sometimes it is difficult 
to know physically where that belongs in 
a genome.” Burgess adds: “The eighth 
version will be a ‘finished’ version like 
human was in 2003, meaning that the 
error rate is about 1 in 50,000 bases and 
all non-repetitive DNA is sequenced. 
There should be no unincorporated 
sequence, which has not been true to 
date.” Researchers believe the complex-
ity and polymorphic nature of the start-Cell 139, ing material—from multiple fish—caused 
initial delays and some express frus-
tration at the speed of the sequencing 
effort. “The availability of the genome is 
transformative and there has been some 
consternation at the pace it has become 
available. But that just speaks to how 
hungry everyone is to have access,” 
according to Randall Peterson of Har-
vard Medical School in Boston.
“Sanger is spending more resources 
to help the zebrafish genome catch up 
with human and mouse,” says neurosci-
entist Monte Westerfield of the University 
of Oregon. “There is an ongoing effort 
by the Sanger VEGA team to annotate 
individual genes and transcripts in col-
laboration with us in Oregon. And then 
ZFIN incorporates data from the litera-
ture. That is significantly improving the 
genome sequence and assembly. And 
that aids in all sorts of experiments.” 
ZFIN is a centralized repository for all 
things “zebbie” and a first port of call for 
anyone interested in starting research on 
zebrafish. It has almost 5000 members.
Embryologist Marnie Halpern of the 
Carnegie Institute of Washington stresses 
the time the Sanger sequence saves, 
pointing out that her lab can confirm 
the identity of a new mutation affecting 
the brain in a matter of months instead 
of years. However, there are still some 
regions of the genome her lab is working 
on where the sequence is poor, causing 
trouble in cloning regulatory regions of a 
gene of interest, for example.
“Recently there has been a second 
wave of researchers looking for creative 
new ways to exploit zebrafish,” says Bur-
gess. Tissue regeneration is one area, 
with studies revealing that fish can regen-
erate heart, nervous tissue, retina, and 
fins. “We are specifically looking at how 
adult hearing regenerates in zebrafish 
after exposure to intense sound or oto-
toxic drugs. My lab uses a mixture of November 25, 2009 ©2009 Elsevier Inc. 843
genetics and genomics approaches to 
define the gene network that activates 
during hearing regeneration,” says Bur-
gess. Hearing loss is permanent in mam-
mals, but all other vertebrates, including 
birds, are able to repair hearing dam-
age, he notes; “Therefore I believe that 
the loss of regenerative ability in mam-
mals must be a relatively recent occur-
rence and perhaps activation of a very 
small set of genes could actually cause 
a ‘reactivation’ of the regeneration pro-
cess. Support for this idea comes from 
the recent discovery that it takes as few 
as four genes to convert somatic cells to 
embryonic stem cells.”
Validating new drug targets remains 
a bottleneck in drug discovery, and the 
fish can help. Most small molecule dis-
covery efforts in industry and academia 
rely on high-throughput screening and 
simplified in vitro reactions or cell-based 
assays, but Peterson is testing those 
same approaches on living zebrafish. 
He has shown that drugs known for their 
effects in humans have similar effects 
in zebrafish larvae. In 2004, Peterson’s 
group screened 5000 small molecules 
and discovered two that overcame a 
blood circulation problem in a mutant 
called gridlock. Large numbers of fish 
can be tested simultaneously because 
early zebrafish embryos measure less 
than a millimeter and several fit in each 
well of a 96-well plate. Peterson notes: 
“In some assays, we screen as many as 
5000 animals per day.” There are also 
benefits from an ethical standpoint, as 
work can be done on embryos rather 
than adults and does not require dissec-
tion, destruction, or invasive imaging of 
the fish.
Peterson uses a robotic micro-
scope to record responses of zebrafish 
embryos or larvae to various stimuli. 
Adding compounds to each well, he can 
assess the way they affect the animal’s 
baseline behavior. His team is using this 
approach to identify new stimulants, 
sedatives, and other behavior-modifying 
compounds that could be used for treat-
ing nervous system disorders such as 
Alzheimer’s disease. In another screen, a 
molecule was discovered that blocks the 
progression of bone overgrowth disease 
and is advancing toward the clinic. “We 
designed a zebrafish screen, screened 
through thousands of molecules and 844 Cell 139, November 25, 2009 ©2009 Eidentified an intriguing molecule. We then 
used chemistry to optimize it, moved it 
into mouse models and showed it was 
effective,” says Peterson.
Uwe Strähle of the University of 
Heidelberg recalls how he was warned 
off the zebrafish with: “Don’t do it. The 
mouse is much, much better.” He feels 
his decision has been amply justified, 
pointing to the almost 5000 mutants 
and transgenic lines for fish, including 
those with altered cholesterol, metabo-
lism, heart physiology, or cancer. And 
he can study systems biology in a live 
and intact organism. “There is an ini-
tiative in early planning stages where 
people in the community are exploring 
whether or not a large scale project to 
knock out every gene in the genome is 
feasible and valuable,” says Peterson. “It 
is clear to me that this isn’t science fic-
tion and we could, in a short period of 
time, be able to deconstruct every gene 
in the zebrafish genome.” Stemple sees 
the fish racing ahead of the mouse: we 
will be able to identify phenotypes for 
all protein-encoding genes well before it 
is done in the mouse, he says (although 
currently the mouse is ahead of the game 
with about 5000 genes deleted, versus 
700 deleted in the zebrafish).
The NIH was an early starter in sup-
porting zebrafish research. “There was 
a lot of excitement over the past years 
at NIH; it seemed like every institute 
wanted to expand their portfolio to 
include zebrafish research,” notes Wes-
terfield. “To a great extent, I think that is 
still true.” Moreover, the community has 
expanded dramatically in just 5 years, 
with capacity numbers at last year’s inter-
national zebrafish conference in Madi-
son, Wisconsin (http://www.union.wisc.
edu/zebrafish/). The big growth area has 
been clinicians wanting to understand the 
basic biology of disease genes. The NIH 
has supported the development of tools 
that would “help promote zebrafish as an 
animal model for studying development 
and diseases,” says Lorette Javois at the 
NIH’s National Institute for Child Health 
& Human Development and a member 
of the Trans-NIH Zebrafish Coordinating 
Committee. “A lot of times those types of 
applications that aren’t strongly hypoth-
esis driven don’t fare well in the standard 
NIH peer review systems,” she adds. “We 
have two different solicitations for appli-lsevier Inc.cations that are currently active. One is 
soliciting research tools and techniques 
generally that would enhance zebrafish 
research; the other is soliciting more 
specifically genetic screens that would 
enhance zebrafish research.” For fiscal 
year 2009, NIH funding for research tools 
and genetic screens totaled almost $11 
million spread over 33 grants.
Meanwhile, the European Commission 
(EC) launched a substantial zebrafish 
project in 2004 (ZF-MODELS), with over 
20 research teams receiving €12 million 
(http://www.zf-models.org/). “This was 
mainly a large scale mutagenesis pro-
gram in zebrafish to identify genes linked 
with development, health and disease,” 
says Jacques Remacle, a scientific offi-
cer with the EC. Another €11 million is 
now being negotiated for a followup 
project, ZF-HEALTH. “We want to build 
on the mutagenesis and understand the 
roles of genes in health and disease,” 
explains Remacle. Other large funders 
include the Dutch government, provid-
ing €14 million spread over several years 
through its Smart Mix program, and the 
Wellcome Trust, which is funding large-
scale TILLING at Sanger as well as most 
of the zebrafish genome sequencing 
project.
Physician scientist Leonard Zon, a 
Howard Hughes investigator at Harvard, 
is renowned for his zebrafish models of 
human disease. He began by creating 
zebrafish mutants that had problems 
making blood cells and worked on the 
first zebrafish mutant that predicted 
a new human disease gene. A recent 
chemical genetics screen using zebrafish 
revealed that prostaglandins stimulate 
blood stem cell production; prostaglan-
din E2 in particular boosted the num-
ber of blood stem cells in zebrafish and 
mice. Zon’s lab is now treating human 
cord blood with prostaglandin E2 to try 
to increase stem cell numbers prior to 
transplant. “Recently we studied a clini-
cal trial for patients with leukemia who 
are getting a cord blood transplant,” he 
explains. “And we are treating the cord 
blood with the chemical that we found in 
zebrafish. So it is an interesting story on 
how zebrafish could facilitate us in find-
ing new therapies for disease.”
Zon also has developed a melanoma 
model in zebrafish and recently discov-
ered a gene that when mutated accel-
erates cancer formation. The gene 
encodes an enzyme, he says, “so in 
theory, if we could make a drug to 
that particular gene product, then 
you would have a new therapy.” 
The advantage of zebrafish cancer 
models is that they absorb small 
molecules directly from the water, 
thereby enabling rapid screening 
for anticancer agents in vivo (Fig-
ure 1). And it is in cancer that the 
zebrafish and its newly sequenced 
genome may gain its stripes. “Early 
tumors are very difficult to detect 
and in most organisms you can’t 
follow them live,” explains Ralf 
Dahm, now at the Spanish National 
Cancer Research Centre in Madrid, 
who managed the ZF-MODELS 
project in Europe. “If you transplant 
a human tumor into the fish, how-
ever, you can visualize the very early 
steps in cancer at high resolution.” 
You can see how the young tumor 
recruits blood vessels and inter-
acts with its microenvironment, and 
how the immune system reacts, he 
notes. A high-quality sequence will 
be critical, and Dahm says even the 
first version released by Sanger in 
2002 helped his research.
Clearly, the fish is not just a poor 
man’s mouse. Cancer biologist Ste-
ven Leach at Johns Hopkins in Bal-
timore, Maryland, relies on zebrafish 
models in addition to mice. His insti-
tute has sequenced the exomes of 
24 different human pancreatic can-
cers, but the challenge now is to 
annotate this vast catch and deter-
mine which mutations contribute to 
cancer pathogenesis. “Traditionally 
that would have been done in the mouse, 
but with this torrent of new data we really 
have a dramatic bottleneck in terms 
of evaluating the significance of these 
mutations,” says Leach. “Based on the 
ease and relative low cost of establishing 
transgenic zebrafish, fish cancer models 
provide significantly higher throughput 
in the functional evaluation of candi-
date oncogenes and tumor suppressor 
genes.”
Over the last decade it has become 
apparent that all vertebrates have the 
same sets of genes, and that biochemi-
cal and developmental pathways are 
highly conserved. Javois at the NIH is 
clear about the zebrafish sequence’s 
potential here: “It allows people to go 
between animal model systems and 
look for homologous genes, so if you 
are working on some other animal 
model on a particular gene or pathway, 
you can look for the equivalent or vice 
versa.” Almost all zebrafish genes have 
been found to have equivalent human 
genes (orthologs). “When I started with 
this model, a large number of people 
thought I was crazy,” notes Zon. A few 
said we don’t even know whether fish 
form blood the same way as humans, 
he recalls. Zon cloned the genes for all 
of his blood mutants, with the help of 
the Sanger sequence, and found 
human orthologs for all of them. 
With 300 million years of evolution 
between fish and humans, he dis-
covered that the same carrier pro-
tein still brings iron from mother or 
yolk to embryo, for example. “With 
a full set of genes from the Sanger 
it is possible to create streams of 
fish for quantitative trait analysis. 
Because of the large number of fish 
you could get, it could really lead to 
an unprecedented jump in science,” 
says Zon.
Stemple, who studies muscular 
dystrophies, stresses the advan-
tages of the speed and scale of 
experiments possible with the 
fish: “In zebrafish you can already 
see the effects of a mutation two 
days after fertilization, so that you 
can usually score a muscular dys-
trophy in zebrafish very early in 
development. That is really useful, 
because you can get rapid devel-
opment, and you can look at liter-
ally hundreds of fish and hundreds 
of genes very quickly. That is why 
people are turning to zebrafish as a 
model organism.”
Researchers increasingly work on 
adult fish, and Dahm is enthusiastic 
about the possibilities of monitoring 
cells in the almost transparent casper 
mutant (Figure 1). Moreover, tech-
niques such as “brainbow,” which 
allows simultaneous labeling of many 
cells with individual “colors,” per-
mit analyses of complex neural net-
works in vivo, he notes. “Using this 
approach to study cell lineages and 
cell diversity in cancer, including test-
ing the importance of the recently identi-
fied cancer stem cells to tumor develop-
ment, clearly is a very exciting potential 
application of brainbow.” Another recent 
development for targeting specific genes 
is zinc finger nuclease technology. “This 
is a really potentially transformative tech-
nology that is going to rapidly accelerate 
reverse genetic approaches in zebrafish, 
such as are commonly applied in mice and 
other model organisms. It obviously relies 
on very precise sequencing of the zebrafish 
genome,” notes Leach. But despite all of 
this progress, as Leach emphasizes, “the 
field still carries the burden of demonstrat-
ing that zebrafish models of cancer truly 
Figure 1. The Zebrafish in Close Up
(Top) BRAFV600E is the most common oncogene in human 
melanomas. Zebrafish carrying mutant p53 and expressing 
a BRAFV600E transgene in melanophore pigment cells develop 
melanomas. (Middle) In the zebrafish casper mutant, develop-
ment of pigment cells is disrupted. These optically clear fish 
are valuable for imaging studies as their internal organs are 
visible. (Bottom) Zebrafish embryos expressing a fluorescent 
protein in their primordial germ cells. Photos courtesy of C. 
Ceol (top), R.M. White (middle), and P. Schlueter and R. Pe-
terson (bottom).Cell 139, November 25, 2009 ©2009 Elsevier Inc. 845
have utility beyond more traditional mouse 
models when it comes to impacting on 
patients with the disease.”
Like all models, the zebrafish is not 
perfect. The tools and techniques to 
manipulate zebrafish genetically are not 
yet as sophisticated as they are for mice, 
notes Dahm. “There are, for instance, 
fewer promoters for tissue-specific 
expression, and targeted mutagenesis is 
only now becoming easier with the new 
zinc finger nucleases,” he says. Anything 
to do with mother-embryo interactions is 
difficult to study, he adds, because fer-
tilization and embryonic development 
are external. Moreover, zebrafish are not 
mammals. “So there are some human 
organs, processes, and physiology that 
you can’t study in zebrafish, such as lung, 
mammary gland, and uterus,” notes Wes-
terfield. The size of the fish is a big advan-
tage for microscopists but can also be a 
drawback when large amounts of tissue 
are required. Even adults are only about 
2 inches long. “Taking blood from one of 
the tiny zebrafish larvae or having to dis-
sect their livers for proteomics analyses, 
although possible, is no trivial task,” says 
Dahm. And though many researchers 846 Cell 139, November 25, 2009 ©2009 Elsthink antisense oligonucleotides called 
morpholinos are the “silver bullet” for 
knocking down genes and studying their 
function, says Westerfield: “Nothing beats 
a heritable mutation, however, and results 
from morpholino studies should be con-
firmed by examining protein expression 
and, ultimately, mutants. Also, for trans-
lational work, therapeutics developed in 
zebrafish will typically need to be tested 
in mammals before moving to humans.”
Despite the drawbacks, charitable 
trusts and foundations are recogniz-
ing the zebrafish’s potential as a model 
organism. For example, Chico has 
received funding from the British Heart 
Foundation, and his institute has just 
received a £1.5 million Medical Research 
Council grant to set up a screening facil-
ity for small molecule drugs. He is also 
using the fish to study arterial occlu-
sions, which are difficult to create in 
other model organisms. He can now 
observe developments in live animals 
and can watch the effects of temporarily 
knocking out genes using morpholinos.
And the fish has returned home, in 
a manner of speaking. The Institute of 
Genomics and Integrative Biology in evier Inc.Delhi, India, has collected wild speci-
mens of Danio rerio from rivers and has 
begun sequencing their genomes using 
next generation sequencing machines. 
The Indian group are using the fish as 
a model to understand within-species 
genetic variation and to complement the 
Sanger sequence. Some researchers 
see this as providing extra impetus for 
Sanger to complete its efforts.
The fish model has migrated beyond 
Europe and the US, with significant 
zebrafish research groups now in Austra-
lia, New Zealand, China, and Singapore. 
According to Zon: “There’s lots of oppor-
tunities for new investigators coming 
into the field and most institutions want 
a zebrafish researcher in their midst.” 
Though there is no such thing as a per-
fect model system, notes Burgess, “the 
zebrafish is valuable because it strikes a 
compromise balance between the large 
number of animals that can be exam-
ined and its relatedness to humans.” 
The zebrafish is underutilized in terms of 
its possibilities, comments Westerfield, 
who is upbeat about its future: “There’s 
plenty of room for folks who have got 
crazy new ideas.”
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